Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L26 pseudogene 35 (RPL26P35) is a processed pseudogene derived from the ribosomal protein L26 gene. In humans, Ribosomal protein L26 is a component of the 60S ribosomal subunit, playing a role in protein synthesis and, to some extent, p53 mRNA regulation. However, the pseudogene RPL26P35 does not produce a functional protein and is considered genomically inert. Processed pseudogenes such as RPL26P35 arise from retrotransposition events and are dispersed throughout the genome; they generally do not have coding capability or regulatory function[1][2][5]. While ribosomal protein L26 and some other ribosomal proteins have been implicated in various cellular processes and disease mechanisms, these roles do not apply to RPL26P35, which is essentially an inactive DNA segment.
None (does not encode protein or act as a molecular target)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L26 pseudogene 35 (RPL26P35).